UBS Maintains Buy on Legend Biotech, Raises Price Target to $81
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Ashwani Verma maintains a Buy rating on Legend Biotech (NASDAQ:LEGN) and raises the price target from $76 to $81.

March 18, 2024 | 2:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Ashwani Verma maintains a Buy rating on Legend Biotech and raises the price target from $76 to $81.
The upgrade in the price target by a reputable analyst like Ashwani Verma from UBS is a strong positive signal for Legend Biotech. It suggests a bullish outlook on the stock's future performance, likely due to anticipated operational successes or financial improvements. This can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100